Literature DB >> 27214611

The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications.

S Björkman1, M Carlsson1.   

Abstract

This article reviews the pharmacokinetics of exogenous factor VIII and factor IX in patients with haemophilia. It focuses on the methodology (and inherent pitfalls) of pharmacokinetic studies, then summarizes available pharmacokinetic data and finally discusses some applications of pharmacokinetics for optimization of prophylactic treatment of haemophilia and for comparison of coagulation factor concentrates. Blackwell Science Ltd.

Entities:  

Keywords:  comparative studies; dosing; factor IX; factor VIII; methodological aspects; pharmacokinetics.

Year:  1997        PMID： 27214611     DOI： 10.1046/j.1365-2516.1997.00074.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  11 in total

1.  Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.

Authors:  Sven Björkman; Victor Ahlén
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Treatment strategies in children with hemophilia.

Authors:  Pia Petrini
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  A system-approach method for the adjustment of time-varying continuous drug infusion in individual patients: a simulation study.

Authors:  Mária Durisová; Ladislav Dedík
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

5.  Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

Authors:  Sven Björkman; Anna Folkesson; Siv Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2009-06-26       Impact factor: 2.953

6.  Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.

Authors:  Alfonso Iorio; Arun Keepanasseril; Gary Foster; Tamara Navarro-Ruan; Alanna McEneny-King; Andrea N Edginton; Lehana Thabane
Journal:  JMIR Res Protoc       Date:  2016-12-15

7.  Optimization of prophylaxis for hemophilia A.

Authors:  Robert D Herbert; Carolyn R Broderick; Chris Barnes; Laurent Billot; Albert Zhou; Jane Latimer
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

8.  Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.

Authors:  Janneke I Loomans; Eva Stokhuijzen; Marjolein Peters; Karin Fijnvandraat
Journal:  J Clin Transl Res       Date:  2018-02-21

9.  Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.

Authors:  Jerome Teitel; Michelle Sholzberg; Alfonso Iorio
Journal:  Res Pract Thromb Haemost       Date:  2021-02-23

10.  Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years.

Authors:  Ju Young Kim; Se Jin Park; Chur Woo You
Journal:  Blood Res       Date:  2021-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.